Novartis Late-Stage Pelacarsen Study Fails, Stock Drops

Earnings
โดย Zacks Investment Research·CHUS·Read original
Summary · why it matters

Novartis announced that its late-stage cardiovascular outcomes study of pelacarsen, an investigational antisense oligonucleotide designed to inhibit lipoprotein(a) production, failed to meet its primary endpoint. The Lp(a)HORIZON trial, which enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease, did not show a significant reduction in major adverse cardiovascular events compared to placebo. Shares of Novartis fell 4.7% in after-hours trading, while Ionis Pharmaceuticals, which discovered pelacarsen and licensed global rights to Novartis, dropped 10%. Amgen also saw a 5% decline in after-hours trading on September 4, as investors worried about the prospects of its similar drug olpasiran. Despite the setback, Novartis continues to rely on growth products like Kisqali and Kesimpta to offset generic competition for Entresto, with 2026 expected to be its largest patent cliff.

Impact on stocks 4

Biotech & Genomic Medicine▼ · 3 stocks
Novartis AG
NOVN
▼ NegativeTechnologyrelevance

Late-stage pelacarsen study failed to meet primary endpoint, causing stock drop.

Ionis Pharmaceuticals Inc
IONS
▼ NegativeTechnologyrelevance

Ionis discovered pelacarsen and licensed rights to Novartis; trial failure directly impacts its drug program.

Amgen Inc
AMGN
▼ NegativeCompetitionrelevance

Investors worried about prospects of Amgen's similar drug olpasiran after Novartis' pelacarsen failed.

Real Estate▲ · 1 stocks
© 2026 MarketDXNews